UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – a phase II randomised trial
The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Hellan Tags: Clinical Trial Source Type: research
Ipilimumab/nivolumab
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
CONCLUSION: Patients with non-small cell lung cancer and a PS of 0-1 who were ineligible for platinum doublet chemotherapy had favorable outcome after the initiation of ICI therapy, and even in patients with a PS of ≥2, they achieved high two-year PFS and OS rates.PMID:38423671 | DOI:10.21873/anticanres.16920 (Source: Cell Research)
Source: Cell Research - February 29, 2024 Category: Cytology Authors: Minehiko Inomata Shuhei Minatoyama Naoki Takata Kana Hayashi Takahiro Hirai Zenta Seto Kotaro Tokui Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Kei Matsuyama Ryuji Hayashi Shoko Matsui Kazuyuki Tobe Source Type: research
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
CONCLUSION: Our work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation.PMID:38383923 | PMC:PMC10881622 | DOI:10.1007/s00432-024-05628-2 (Source: Cell Research)
Source: Cell Research - February 22, 2024 Category: Cytology Authors: Ludmila Krizova Iva Benesova Petra Zemanova Jan Spacek Zuzana Strizova Zuzana Humlova Veronika Mikulova Lubos Petruzelka Michal Vocka Source Type: research
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
CONCLUSION: Our work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation.PMID:38383923 | PMC:PMC10881622 | DOI:10.1007/s00432-024-05628-2 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 22, 2024 Category: Cancer & Oncology Authors: Ludmila Krizova Iva Benesova Petra Zemanova Jan Spacek Zuzana Strizova Zuzana Humlova Veronika Mikulova Lubos Petruzelka Michal Vocka Source Type: research
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
ConclusionOur work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
CONCLUSION: Each ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients.PMID:38372756 | DOI:10.1007/s00228-024-03647-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Clara Oliveira Beatrice Mainoli Gon çalo S Duarte Tiago Machado Rita G Tinoco Miguel Esperan ça-Martins Joaquim J Ferreira Jo ão Costa Source Type: research
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
CONCLUSION: Each ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients.PMID:38372756 | DOI:10.1007/s00228-024-03647-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Clara Oliveira Beatrice Mainoli Gon çalo S Duarte Tiago Machado Rita G Tinoco Miguel Esperan ça-Martins Joaquim J Ferreira Jo ão Costa Source Type: research
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
ConclusionEach ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 19, 2024 Category: Drugs & Pharmacology Source Type: research
Effect of CTLA-4 Inhibition on Inflammation and Apoptosis After Spinal Cord Injury
This study aimed to investigate the influence of CTLA-4 on SCI. A weight-drop technique was used to establish a rat model of SCI. To examine the safeguarding effect of CTLA-4 on the restoration of motor function in rats with SCI, the Basso-Beattie-Bresnahan (BBB) scale and inclined plane test were employed to assess locomotion. Neuronal degeneration and apoptosis were assessed using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) and Fluoro-Jade B labeling, respectively, and the activity of microglial cells was examined by immunofluorescence. To evaluate the impact of CTLA4 on SCI, the levels...
Source: Neurochemical Research - February 17, 2024 Category: Neuroscience Authors: Wei Mao Feng Jiang Chunping Zhu Jun Liu Zhao Lu Yinwei Qian Jinchun Xiao Source Type: research
